Anti-interleukin-1 agents in adult onset still's disease

International Journal of Inflammation

Volumn 2012, Issue , 2012, Pages

  Giampietro, Cecilia ^a   Fautrel, Bruno ^b,c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CANAKINUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GEVOKIZUMAB; GLUCOCORTICOID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA RECEPTOR ANTAGONIST; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REGENERON; RILONACEPT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADULT ONSET STILL DISEASE; AUTOIMMUNITY; BINDING AFFINITY; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DIAPEDESIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BINDING; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVATION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; INFECTION; INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INNATE IMMUNITY; MONOTHERAPY; MYCOSIS; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TH17 CELL; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 84876511603     PISSN: 20908040     EISSN: 20420099     Source Type: Journal    
DOI: 10.1155/2012/317820     Document Type: Review

References (55)

1. Kontzias A., Efthimiou P., Adult-onset still's disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs 2008 68 3 319 337 2-s2.0-38949089775 10.2165/00003495-200868030-00005 (Pubitemid 351225811)
2. Fautrel B., Adult-onset Still disease. Best Practice and Research 2008 22 5 773 792 2-s2.0-56349163043 10.1016/j.berh.2008.08.006
3. Kalliolias G. D., Georgiou P. E., Antonopoulos I. A., Andonopoulos A. P., Liossis S. N. C., Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Annals of the Rheumatic Diseases 2007 66 6 842 843 2-s2.0-34249799278 10.1136/ard.2006.066381 (Pubitemid 46846715)
4. Church L. D., Cook G. P., McDermott M. F., Primer: inflammasomes and interleukin 1 β in inflammatory disorders. Nature Clinical Practice Rheumatology 2008 4 1 34 42 2-s2.0-38049083888 10.1038/ncprheum0681
5. Sidiropoulos P. I., Goulielmos G., Voloudakis G. K., Petraki E., Boumpas D. T., Inflammasomes and rheumatic diseases: evolving concepts. Annals of the Rheumatic Diseases 2008 67 10 1382 1389 2-s2.0-53149123653 10.1136/ard.2007. 078014
6. Guarda G., So A., Regulation of inflammasome activity. Immunology 2010 130 3 329 336 2-s2.0-77953488157 10.1111/j.1365-2567.2010.03283.x
7. Lamkanfi M., Dixit V. M., Inflammasomes: guardians of cytosolic sanctity. Immunological Reviews 2009 227 1 95 105 2-s2.0-58049202273 10.1111/j.1600-065X. 2008.00730.x
8. Wittmann M., Kingsbury S. R., McDermott M. F., m.mcdermott@leeds.ac.uk Is caspase 1 central to activation of interleukin-1? Joint Bone Spine 2011 78 4 327 330 10.1016/j.jbspin.2011.02.004
9. Joosten L. A. B., Netea M. G., Fantuzzi G., Koenders M. I., Helsen M. M. A., Sparrer H., Pham C. T., Van Der Meer J. W. M., Dinarello C. A., Van Den Berg W. B., Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1 β Arthritis & Rheumatism 2009 60 12 3651 3662 2-s2.0-73249144903 10.1002/art.25006
10. Dinarello C. A., Biologic basis for interleukin-1 in disease. Blood 1996 87 6 2095 2147 2-s2.0-0029979369 (Pubitemid 26086851)
11. Gabay C., Lamacchia C., Palmer G., IL-1 pathways in inflammation and human diseases. Nature Reviews Rheumatology 2010 6 4 232 241 2-s2.0-77950627242 10.1038/nrrheum.2010.4
12. Ghoreschi K., Laurence A., Yang X. P., Tato C. M., McGeachy M. J., Konkel J. E., Ramos H. L., Wei L., Davidson T. S., Bouladoux N., Grainger J. R., Chen Q., Kanno Y., Watford W. T., Sun H. W., Eberl G., Shevach E. M., Belkaid Y., Cua D. J., Chen W., O'Shea J. J., Generation of pathogenic TH 17 cells in the absence of TGF- β 2 signalling. Nature 2010 467 7318 967 971 2-s2.0-77958584113 10.1038/nature09447
13. Chen Z., O'Shea J. J., Regulation of IL-17 production in human lymphocytes. Cytokine 2008 41 2 71 78 2-s2.0-38949155203 10.1016/j.cyto.2007.09. 009
14. Lee W. W., Kang S. W., Choi J., Lee S. H., Shah K., Eynon E. E., Flavell R. A., Kang I., Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 2010 115 3 530 540 2-s2.0-77449112013 10.1182/blood-2009-08- 236521
15. Waite J., Skokos D., Th17 Response and inflammatory autoimmune diseases. International Journal of Inflammation 2012 2012 10 819467
16. Chen D. Y., Chen Y. M., Lan J. L., Lin C. C., Chen H. H., Hsieh C. W., Potential role of th17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology 2010 49 12 2305 2312 2-s2.0-78549270112 10.1093/rheumatology/ keq284
17. Gross O., Thomas C. J., Guarda G., greta.guarda@unil.ch Tschopp J., The inflammasome: an integrated view. Immunological Reviews 2011 243 1 136 151 10.1111/j.1600-065X.2011.01046.x
18. Schroder K., The inflammasomes. Cell 2011 140 6 821 832
19. Arima K., Kinoshita A., Mishima H., Kanazawa N., Kaneko T., Mizushima T., Ichinose K., Nakamura H., Tsujino A., Kawakami A., Matsunaka M., Kasagi S., Kawano S., Kumagai S., Ohmura K., Mimori T., Hirano M., Ueno S., Tanaka K., Tanaka M., Toyoshima I., Sugino H., Yamakawa A., Tanaka K., Niikawa N., Furukawa F., Murata S., Eguchi K., Ida H., ida@med.kurume-u.ac.jp Yoshiura K. -I., kyoshi@nagasaki-u.ac.jp Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proceedings of the National Academy of Sciences of the United States of America 2011 108 36 14914 14919 10.1073/pnas.1106015108
20. Dinarello C. A., cdinarello@mac.com Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011 117 14 3720 3732 10.1182/blood-2010-07-273417
21. Hoshino T., Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. The Journal of Rheumatology 1998 25 2 396 398 (Pubitemid 128753755)
22. Kötter I., Wacker A., Koch S., Henes J., Richter C., Engel A., Günaydin I., Kanz L., Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Seminars in Arthritis & Rheumatism 2007 37 3 189 197 2-s2.0-34547878809 10.1016/j.semarthrit.2007.04.002 (Pubitemid 350151506)
23. Kontzias A., Efthimiou P., Adult-onset still's disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs 2008 68 3 319 337 2-s2.0-38949089775 10.2165/00003495-200868030-00005 (Pubitemid 351225811)
24. Youm J. Y., Woo J. H., Kim T. H., Bae S. C., Yoo D. H., Interleukin-1 β and interleukin-1 receptor antagonist gene polymorphisms in Korean patients with adult-onset Still's disease. Scandinavian Journal of Rheumatology 2007 36 5 390 393 2-s2.0-35648963744 10.1080/03009740701340081 (Pubitemid 350034819)
25. H1-inducing, proinflammatory cytokine and new member of the IL-1 family. Journal of Allergy and Clinical Immunology 1999 103 1 11 24 2-s2.0-0032607876 (Pubitemid 29063184)
26. Yoshida Y., Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant Adult-Onset Still's disease. Internal Medicine 2011 50 1757 1760
27. Kontzias A., Comparative cytokine analysis across a spectrum of genetically and/or clinically defined auto-inflammatory syndromes. Arthritis & Rheumatism 2011 63 supplement 10, article 60
28. Priori R., rob.pri@libero.it Barone F., Alessandri C., Colafrancesco S., McInnes I. B., Pitzalis C., Valesini G., Bombardieri M., Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis. Rheumatology 2011 50 4 776 780 10.1093/rheumatology/keq397
29. Chen D. Y., Lan J. L., Lin F. J., Hsieh T. Y., Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset still's disease. Journal of Rheumatology 2004 31 11 2189 2198 2-s2.0-7544248841
30. Maier J., Birkenfeld G., Pfirstinger J., Schölmerich J., Fleck M., Brühl H., Effective treatment of steroid refractory adult-onset Still's disease with anakinra. Journal of Rheumatology 2008 35 5 939 941 2-s2.0-44349141302 (Pubitemid 351747145)
31. Raffeiner B., Botsios C., Dinarello C., Ometto F., Punzi L., Ramonda R., Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine 2011 78 1 100 101 2-s2.0-77958591067 10.1016/j.jbspin.2010.09.014
32. Vasques Godinho F. M., Parreira Santos M. J., Canas Da Silva J., Refractory adult onset Still's disease successfully treated with anakinra. Annals of the Rheumatic Diseases 2005 64 4 647 648 2-s2.0-16344364963 10.1136/ard.2004.026617 (Pubitemid 40469103)
33. Fitzgerald A. A., LeClercq S. A., Yan A., Homik J. E., Dinarello C. A., Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis & Rheumatism 2005 52 6 1794 1803 2-s2.0-18644370644 10.1002/art.21061 (Pubitemid 40852888)
34. Lequerré T., thierry.lequerre@univ-rouen.fr Quartier P., quartier@necker.fr Rosellini D., Alaoui F., De Bandt M., Mejjad O., Kone-Paut I., Michel M., Demis E., Khellaf M., Limai N., Job-Deslandre C., Fautrel B., Le Loët X., Sibilia J., Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Annals of the Rheumatic Diseases 2008 67 3 302 308 10.1136/ard.2007.076034 (Pubitemid 351281262)
35. Naumann L., Feist E., Natusch A., Langen S., Krause A., Buttgereit F., Burmester G. R., IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Annals of the Rheumatic Diseases 2010 69 2 466 467 2-s2.0-75749100258 10.1136/ard.2009.108068
36. Laskari K., katerinalaskari@yahoo.gr Tzioufas A. G., agtzi@med.uoa.gr Moutsopoulos H. M., hmoutsop@med.uoa.gr Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study. Arthritis Research and Therapy 2011 13 3, article R91 10.1186/ar3366
37. Fautrel B., Sibilia J., Mariette X., Combe B., Tumour necrosis factor α blocking agents in refractory adult Still's disease: an observational study of 20 cases. Annals of the Rheumatic Diseases 2005 64 2 262 266 2-s2.0-13244252641 10.1136/ard.2004.024026 (Pubitemid 40193624)
38. Giampietro C., Long term treatment with anakinra in patients with Adult-onset Still Disease. Arthritis & Rheumatism 2010 62 supplement 10, article 902
39. Fautrel B., Borget C., Rozenberg S., Meyer O., Le Loët X., Masson C., Koeger A. C., Kahn M. F., Bourgeois P., Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. Journal of Rheumatology 1999 26 2 373 378 2-s2.0-0032954456 (Pubitemid 29066742)
40. Moulis G., Sailler L., Astudillo L., Pugnet G., Arlet P., May anakinra be used earlier in adult onset Still disease? Clinical Rheumatology 2011 29 10 1199 1200 2-s2.0-77951228458 10.1007/s10067-010-1459-6
41. Fleishmann R. M., Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF- α agents. Clinical and Experimental Rheumatology 2002 20 5, supplement 27 S35 S41 2-s2.0-0036400157 (Pubitemid 35174752)
42. Singh J. A., Wells G. A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J. K., Filippini G., Skoetz N., Francis D., Lopes L. C., Guyatt G. H., Schmitt J., La Mantia L., Weberschock T., Roos J. F., Siebert H., Hershan S., Lunn M. P., Tugwell P., Buchbinder R., Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews (Online) 2011 2, article CD008794
43. Guignard S., Dien G., Dougados M., Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report. Clinical and Experimental Rheumatology 2007 25 5 758 759 2-s2.0-37349007708 (Pubitemid 350284852)
44. Quartuccio L., De Vita S., Interleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still's disease. Journal of Rheumatology 2007 34 4 892 893 2-s2.0-34247324391 (Pubitemid 46641410)
45. Botsios C., Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmunity Reviews 2005 4 3 162 170 2-s2.0-16844386174 10.1016/j.autrev.2004.09.001 (Pubitemid 40488745)
46. Stahl N., Radin A., Mellis S., RilonaceptCAPS and beyond: a scientific journey. Annals of the New York Academy of Sciences 2009 1182 124 134 2-s2.0-73849143947 10.1111/j.1749-6632.2009.05074.x
47. Henderson, Safety and efficacy of IL-1 trap in resistant adult onset Still's disease: 24 month follow-up of open label treatment and biomarkers of response. Arthritis & Rheumatism 2010 62 supplement 10 1831
48. Dhimolea E., Canakinumab. mAbs 2010 2 1 3 13 2-s2.0-77953665294 10.4161/mabs.2.1.10328
49. Hoffman H. M., Therapy of autoinflammatory syndromes. Journal of Allergy and Clinical Immunology 2009 124 6 1129 1138 2-s2.0-71149101614 10.1016/j.jaci.2009.11.001
50. Goldbach-Mansky R., Blocking interleukin-1 in rheumatic diseases: its initial disappointments and recent successes in the treatment of autoinflammatory diseases. Annals of the New York Academy of Sciences 2009 1182 111 123 2-s2.0-73849134001 10.1111/j.1749-6632.2009.05159.x
51. Lachmann H. J., Kone-Paut I., Kuemmerle-Deschner J. B., Leslie K. S., Hachulla E., Quartier P., Gitton X., Widmer A., Patel N., Hawkins P. N., Use of canakinumab in the cryopyrin-associated periodic syndrome. The New England Journal of Medicine 2009 360 23 2416 2425 2-s2.0-66649102432 10.1056/NEJMoa0810787
52. Hoffman H. M., Throne M. L., Amar N. J., Sebai M., Kivitz A. J., Kavanaugh A., Weinstein S. P., Belomestnov P., Yancopoulos G. D., Stahl N., Mellis S. J., Efficacy and safety of rilonacept (Interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis & Rheumatism 2008 58 8 2443 2452 2-s2.0-49449094179 10.1002/art.23687
53. Eline A., Rilonacept and canakinumab. British Journal of Clinical Pharmacology 2011 71 5 639 641
54. Geiler J., McDermott M. F., m.mcdermott@leeds.ac.uk Gevokizumab, an anti-IL-1 β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Current Opinion in Molecular Therapeutics 2010 12 6 755 769
55. Gül A., agul@istanbul.edu.tr Tugal-Tutkun I., Dinarello C. A., Reznikov L., Artim Esen B., Mirza A., Scannon P., Solinger A., Interleukin-1-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Annals of the Rheumatic Diseases 2012 71 4 563 566 10.1136/annrheumdis-2011-155143